Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 409

1.

Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.

Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.

Curr Opin Pulm Med. 2018 Feb 20. doi: 10.1097/MCP.0000000000000477. [Epub ahead of print]

PMID:
29470252
2.

Adolescents and young adults: a neglected population group for tuberculosis surveillance.

García-Basteiro AL, Schaaf HS, Diel R, Migliori GB.

Eur Respir J. 2018 Feb 21;51(2). pii: 1800176. doi: 10.1183/13993003.00176-2018. Print 2018 Feb. No abstract available.

PMID:
29467211
3.

Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.

Tadolini M, Tiberi S, Migliori GB.

Lancet Infect Dis. 2018 Feb 13. pii: S1473-3099(18)30106-3. doi: 10.1016/S1473-3099(18)30106-3. [Epub ahead of print] No abstract available.

PMID:
29452940
4.

Point of care diagnostics for tuberculosis.

García-Basteiro AL, DiNardo A, Saavedra B, Silva DR, Palmero D, Gegia M, Migliori GB, Duarte R, Mambuque E, Centis R, Cuevas LE, Izco S, Theron G.

Rev Port Pneumol (2006). 2018 Feb 6. pii: S2173-5115(17)30183-5. doi: 10.1016/j.rppnen.2017.12.002. [Epub ahead of print]

5.

Diagnostic performances of the Xpert MTB/RIF in Brazil.

Silva DR, Sotgiu G, D'Ambrosio L, Pereira GR, Barbosa MS, Dias NJD, Saderi L, Centis R, Migliori GB.

Respir Med. 2018 Jan;134:12-15. doi: 10.1016/j.rmed.2017.11.012. Epub 2017 Nov 21.

PMID:
29413498
6.

Tuberculosis elimination: a dream or a reality? The case of Oman.

Al Yaquobi F, Al-Abri S, Al-Abri B, Al-Abaidani I, Al-Jardani A, D'Ambrosio L, Centis R, Matteelli A, Manissero D, Migliori GB.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702027. doi: 10.1183/13993003.02027-2017. Print 2018 Jan. No abstract available.

PMID:
29326321
7.

Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone.

Alffenaar JWC, Peloquin CA, Migliori GB.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):2. doi: 10.5588/ijtld.17.0632. No abstract available.

PMID:
29297417
8.

Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens.

Cabibbe AM, Sotgiu G, Izco S, Migliori GB.

Eur Respir J. 2017 Dec 28;50(6). pii: 1702292. doi: 10.1183/13993003.02292-2017. Print 2017 Dec. No abstract available.

PMID:
29284689
9.

Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress.

Garcia-Basteiro AL, Wong E, Van Oort PM, Cilloniz C, Migliori GB, Singanayagam A.

J Thorac Dis. 2017 Nov;9(Suppl 16):S1559-S1562. doi: 10.21037/jtd.2017.11.39. No abstract available.

10.

Prevention of tuberculosis transmission through medical surveillance systems.

Sotgiu G, Migliori GB.

Lancet Public Health. 2017 Oct;2(10):e439-e440. doi: 10.1016/S2468-2667(17)30179-2. Epub 2017 Oct 3. No abstract available.

11.

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

D'Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB.

Rev Port Pneumol (2006). 2017 Dec 8. pii: S2173-5115(17)30163-X. doi: 10.1016/j.rppnen.2017.10.005. [Epub ahead of print]

12.

Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.

Amicosante M, D'Ambrosio L, Munoz M, Mello FCQ, Tebruegge M, Chegou NN, Seghrouchni F, Centis R, Goletti D, Bothamley G, Migliori GB; TB Diagnostic Survey Working Group.

J Bras Pneumol. 2017 Sep-Oct;43(5):380-392. doi: 10.1590/S1806-37562017000000219. English, Portuguese.

13.

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.

Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701462. doi: 10.1183/13993003.01462-2017. Print 2017 Nov. No abstract available.

PMID:
29146605
14.

Bedaquiline: how better to use it.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701670. doi: 10.1183/13993003.01670-2017. Print 2017 Nov. No abstract available.

PMID:
29122921
15.

Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.

Falzon D, Migliori GB, Jaramillo E, Weyer K, Joos G, Raviglione M; Global Task Force on digital health for TB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701632. doi: 10.1183/13993003.01632-2017. Print 2017 Nov. No abstract available.

PMID:
29122920
16.

Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?

Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Int J Infect Dis. 2017 Dec;65:133-134. doi: 10.1016/j.ijid.2017.10.019. Epub 2017 Nov 6. No abstract available.

17.

Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.

Luzzati R, Migliori GB, Zignol M, Cirillo DM, Maschio M, Tominz R, Ventura G, Patussi V, D'Ambrosio L, Centis R, Michieletto F, Trovato A, Salton F, Busetti M, Di Santolo M, Raviglione M, Confalonieri M.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701414. doi: 10.1183/13993003.01414-2017. Print 2017 Nov. No abstract available.

PMID:
29097434
18.

Roadmap for Tuberculosis Elimination in Latin America and the Caribbean.

Torres-Duque CA, Fuentes Alcalá ZM, Rendón A, Migliori GB.

Arch Bronconeumol. 2018 Jan;54(1):7-9. doi: 10.1016/j.arbres.2017.07.004. Epub 2017 Oct 6. English, Spanish. No abstract available.

19.

X-Rays from the Location of the Double-humped Transient ASASSN-15lh.

Margutti R, Metzger BD, Chornock R, Milisavljevic D, Berger E, Blanchard PK, Guidorzi C, Migliori G, Kamble A, Lunnan R, Nicholl M, Coppejans DL, Dall'Osso S, Drout MR, Perna R, Sbarufatti B.

Astrophys J. 2017 Feb 10;836(1). pii: 25. doi: 10.3847/1538-4357/836/1/25. Epub 2017 Feb 6.

20.

Post-implementation blues: the unfulfilled potential of Xpert.

Tiberi S, Pontali E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1073. doi: 10.5588/ijtld.17.0478. No abstract available.

PMID:
28911347
21.

Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

Alffenaar JC, Migliori GB, Gumbo T.

Lancet Infect Dis. 2017 Sep;17(9):898. doi: 10.1016/S1473-3099(17)30449-8. No abstract available.

PMID:
28845791
22.

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB.

J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16. Review.

23.

Understanding the multidrug-resistant tuberculosis epidemic in China.

Centis R, D'Ambrosio L, Migliori GB.

Int J Tuberc Lung Dis. 2017 Sep 1;21(9):955. doi: 10.5588/ijtld.17.0438. No abstract available.

PMID:
28826442
24.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

25.

A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium.

D'Ambrosio L, Tadolini M, Centis R, Chalmers JD, Migliori GB.

Indian J Med Res. 2017 Mar;145(3):261-263. doi: 10.4103/ijmr.IJMR_37_17. No abstract available.

26.

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700648. doi: 10.1183/13993003.00648-2017. Print 2017 Jul. No abstract available.

PMID:
28679614
27.

Tuberculosis control, and the where and why of artificial intelligence.

Doshi R, Falzon D, Thomas BV, Temesgen Z, Sadasivan L, Migliori GB, Raviglione M.

ERJ Open Res. 2017 Jun 21;3(2). pii: 00056-2017. doi: 10.1183/23120541.00056-2017. eCollection 2017 Apr. Review.

28.

Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.

de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Framarini M, Tauceri F, Migliori G, Brolli C, Gentili G, Petracci E, Nanni O, Riccobon A, Ridolfi R, Guidoboni M.

Melanoma Res. 2017 Aug;27(4):351-357. doi: 10.1097/CMR.0000000000000356.

PMID:
28654547
29.

Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences.

Dara M, Sulis G, Centis R, D'Ambrosio L, de Vries G, Douglas P, Garcia D, Jansen N, Zuroweste E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):727-736. doi: 10.5588/ijtld.16.0940.

PMID:
28633696
30.

Tuberculosis, alcohol and tobacco: Dangerous liaisons.

Santos-Silva AF, Migliori GB, Duarte R.

Rev Port Pneumol (2006). 2017 Jul - Aug;23(4):177-178. doi: 10.1016/j.rppnen.2017.05.001. Epub 2017 May 31. No abstract available.

31.

Standard operating procedures for tuberculosis care.

Solovic I, Abubakar I, Sotgiu G, Dara M, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Ward B, Teixeira V, Gratziou C, Migliori GB.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700515. doi: 10.1183/13993003.00515-2017. Print 2017 Jun. No abstract available.

PMID:
28572129
32.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

PMID:
28529205
33.

The long and winding road of chest radiography for tuberculosis detection.

Miller C, Lonnroth K, Sotgiu G, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700364. doi: 10.1183/13993003.00364-2017. Print 2017 May. No abstract available.

PMID:
28529204
34.

Nontuberculous mycobacterial pulmonary disease: an increasing burden with substantial costs.

Prevots DR, Loddenkemper R, Sotgiu G, Migliori GB.

Eur Respir J. 2017 Apr 26;49(4). pii: 1700374. doi: 10.1183/13993003.00374-2017. Print 2017 Apr. No abstract available.

PMID:
28446563
35.

Effectiveness of post-migration tuberculosis screening.

Sotgiu G, Migliori GB.

Lancet Infect Dis. 2017 Jul;17(7):684-685. doi: 10.1016/S1473-3099(17)30167-6. Epub 2017 Apr 11. No abstract available.

PMID:
28410980
36.

Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.

Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Arakaki Sanchez D, Dockhorn F, Centis R, Migliori GB.

Eur Respir J. 2017 Apr 12;49(4). pii: 1602309. doi: 10.1183/13993003.02309-2016. Print 2017 Apr. No abstract available.

PMID:
28404651
37.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
38.

Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.

Pontali E, D'Ambrosio L, Centis R, Sotgiu G, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1700146. doi: 10.1183/13993003.00146-2017. Print 2017 Mar. No abstract available.

PMID:
28331046
39.

Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.

Dalcolmo M, Gayoso R, Sotgiu G, D'Ambrosio L, Rocha JL, Borga L, Fandinho F, Braga JU, Galesi VM, Barreira D, Sanchez DA, Dockhorn F, Centis R, Caminero JA, Migliori GB.

Eur Respir J. 2017 Mar 22;49(3). pii: 1602445. doi: 10.1183/13993003.02445-2016. Print 2017 Mar.

PMID:
28331044
40.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

PMID:
28331034
41.

Tuberculosis elimination and the challenge of latent tuberculosis.

Matteelli A, Sulis G, Capone S, D'Ambrosio L, Migliori GB, Getahun H.

Presse Med. 2017 Mar;46(2 Pt 2):e13-e21. doi: 10.1016/j.lpm.2017.01.015. Epub 2017 Mar 6. Review.

PMID:
28279508
42.

The challenge of the new tuberculosis drugs.

Tiberi S, Buchanan R, Caminero JA, Centis R, Arbex MA, Salazar M, Potter J, Migliori GB.

Presse Med. 2017 Mar;46(2 Pt 2):e41-e51. doi: 10.1016/j.lpm.2017.01.016. Epub 2017 Feb 28. Review. French.

PMID:
28256383
43.

World TB Day 2017: Advances, Challenges and Opportunities in the "End-TB" Era.

Petersen E, Maeurer M, Marais B, Migliori GB, Mwaba P, Ntoumi F, Vilaplana C, Kim K, Schito M, Zumla A.

Int J Infect Dis. 2017 Mar;56:1-5. doi: 10.1016/j.ijid.2017.02.012. Epub 2017 Feb 21. No abstract available.

44.

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.

Migliori GB, Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Tiberi S, Tadolini M, Esposito S.

Int J Mol Sci. 2017 Feb 7;18(2). pii: E341. doi: 10.3390/ijms18020341. Review.

45.

De-isolation of patients with pulmonary tuberculosis after start of treatment - clear, unequivocal guidelines are missing.

Petersen E, Khamis F, Migliori GB, Bay JG, Marais B, Wejse C, Zumla A.

Int J Infect Dis. 2017 Mar;56:34-38. doi: 10.1016/j.ijid.2017.01.029. Epub 2017 Feb 3. Review.

46.

Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.

Blasi F, Matteelli A, Sotgiu G, Cirillo DM, Palmieri F, Fattorini L, Migliori GB.

Eur Respir J. 2017 Feb 2;49(2). pii: 1602242. doi: 10.1183/13993003.02242-2016. Print 2017 Feb. No abstract available.

PMID:
28153873
47.

Target regimen profiles for treatment of tuberculosis: a WHO document.

Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M.

Eur Respir J. 2017 Jan 25;49(1). pii: 1602352. doi: 10.1183/13993003.02352-2016. Print 2017 Jan. No abstract available.

48.

Management of extensively drug-resistant tuberculosis.

Centis R, Sotgiu G, Migliori GB.

Lancet Respir Med. 2017 Apr;5(4):237-239. doi: 10.1016/S2213-2600(16)30437-4. Epub 2017 Jan 19. No abstract available.

PMID:
28109868
49.

Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.

Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, Torres-Cruz A, Flores-Vergara H, Martínez-Mendoza D, García-Sancho C, Centis R, Salazar-Lezama MÁ, Pérez-Padilla R.

Arch Bronconeumol. 2017 May;53(5):245-250. doi: 10.1016/j.arbres.2016.10.021. Epub 2017 Jan 11. English, Spanish.

50.

Supplemental Content

Loading ...
Support Center